AQP4 antibody-positive Thai cases: Clinical features and diagnostic problems

Neurology

Volumn 77, Issue 9, 2011, Pages 827-834

  Siritho, S ^a   Nakashima, I ^b   Takahashi, T ^b,c   Fujihara, K ^b   Prayoonwiwat, N ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Yonezawa National Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; AUTOANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; BIOLOGICAL MARKER;

ADULT; ANTIBODY DETECTION; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLASSIC MULTIPLE SCLEROSIS; CLINICAL FEATURE; CLINICALLY ISOLATED SYNDROME; CONTROLLED STUDY; DEMYELINATING DISEASE; DIAGNOSTIC ERROR; DISEASE CLASSIFICATION; FEMALE; HUMAN; INFLAMMATORY DEMYELINATING CENTRAL NERVOUS SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC SPINAL MULTIPLE SCLEROSIS; PLEOCYTOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROPREVALENCE; SPINAL CORD LESION; THAILAND; VERTEBRA BODY; ADOLESCENT; ASIAN; BIOSYNTHESIS; BLOOD; CELL STRAIN HEK293; COMPARATIVE STUDY; ETHNOLOGY; IMMUNOLOGY; MIDDLE AGED; PREVALENCE;

ADOLESCENT; ADULT; AQUAPORIN 4; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; BIOLOGICAL MARKERS; DEMYELINATING AUTOIMMUNE DISEASES, CNS; FEMALE; HEK293 CELLS; HUMANS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; PREVALENCE; RETROSPECTIVE STUDIES; THAILAND; YOUNG ADULT;

EID: 80055078651     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31822c61b1     Document Type: Article

References (40)

1. O'Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996;60:382-387. (Pubitemid 26118744)
2. Wingerchuk DM, Hogancamp WF, O'Brien PC, WeinshenkerBG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114. (Pubitemid 29442132)
3. Cree BA, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol 2002;22:105-122. (Pubitemid 35425276)
4. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-2112. (Pubitemid 39626806)
5. Weinshenker BG, Wingerchuk DM. Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol 2008;318:343-356.
6. Weinshenker BG, Wingerchuk DM, Nakashima I, Fujihara K, Lennon VA. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 2006;5:110-111. (Pubitemid 43107844)
7. Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010;67:1016-1017.
8. Shimizu J, Hatanaka Y, Hasegawa M, et al. IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010;75:1423-1427.
9. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489. (Pubitemid 43958540)
10. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815. (Pubitemid 47238676)
11. Weinshenker BG. Neuromyelitis optica in Western countries: establishing diagnostic criteria and characterization of the spectrum. Neurol Asia 2008;13:161-166.
12. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65:1479-1482. (Pubitemid 41552787)
13. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72:712-717.
14. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-127. (Pubitemid 37443332)
15. Osoegawa M, Kira J, Fukazawa T, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler 2009;15:159-173.
16. Chong HT. Multiple sclerosis in South East Asia and diagnostic criteria for Asians. Neurol Asia 2008;13: 145-146.
17. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180-185. (Pubitemid 18036832)
18. Filippi M, Rocca MA. MR imaging of Devic's neuromyelitis optica. Neurol Sci 2004;25(suppl 4):S371-S373. (Pubitemid 39600435)
19. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-968. (Pubitemid 44036298)
20. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-396.
21. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol 2005;58:840-846. (Pubitemid 41746873)
22. Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000;21:702-706. (Pubitemid 30210434)
23. Takahashi T, Fujihara K, Nakashima I, et al. Antiaquaporin- 4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-243. (Pubitemid 47355956)
24. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study: the European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis 1996;55:116-121.
25. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452. (Pubitemid 14237132)
26. Kim W, Park MS, Lee SH, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler 2010;16: 1229-1236.
27. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130:1224-1234. (Pubitemid 47355951)
28. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009;80:575-577.
29. Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75:208-216.
30. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66:617-629.
31. Siritho S, Prayoonwiwat N. A retrospective study of multiple sclerosis in Siriraj Hospital, Bangkok, Thailand. Can J Neurol Sci 2007;34:99-104. (Pubitemid 46423351)
32. de Seze J, Arndt C, Jeanjean L, et al. Relapsing inflammatory optic neuritis: is it neuromyelitis optica? Neurology 2008;70:2075-2076.
33. Yanagawa K, Kawachi I, Toyoshima Y, et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009;73:1628-1637.
34. Misu T, Fujihara K, Nakashima I, et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002;125:2460-2468. (Pubitemid 35303505)
35. Nakashima I, Fukazawa T, Ota K, et al. Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features. J Neurol 2007;254:488-492. (Pubitemid 46786725)
36. Watanabe S, Misu T, Miyozawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007;13:968-974. (Pubitemid 351541430)
37. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66: 1128-1133.
38. Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist 2007;13:2-11. (Pubitemid 46095579)
39. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120: 2059-2069. (Pubitemid 27493740)
40. Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131:3072-3080.